After buying Novan’s assets, Ligand crosses FDA finish line with molluscum gel Zelsuvmi

Fierce Pharma January 7, 2024
Eric Sagonowsky

Less than six months after Ligand Pharmaceuticals swooped in to buy Novan’s assets following the latter company’s bankruptcy, the purchase has paid off with an FDA approval.

Late Friday, the FDA approved Ligand’s Zelsuvmi for the treatment of molluscum contagiosum in patients ages 1 and older. With the nod, Ligand’s topical gel becomes the first treatment for the highly contagious viral skin infection.

Zelsuvmi can be applied by patients, parents or others at home to treat a condition that’s marked by lesions on a the skin.

The FDA approved the drug based on a pair of phase 3 studies that enrolled a total of 1,598 patients. In the B-SIMPLE 2 and B-SIMPLE4 studies, the drug showed an ability...

Today's Sponsors

Today's Sponsor